PATENT CLAIM ANALYSIS

Application Number: 15952934
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-11
Patent Classification: ["514", "171000"]

Abstract:
The present invention relates to solid oral formulations comprising a compound of formula (3Z,5S)-5-(hydroxymethyl)-1-[(2′-methyl-1,1′-biphenyl-4-yl)carbonyl]pyrrolidin-3-one-O-methyloxime, and/or an active metabolite thereof, and the use of said formulations in the treatment and/or prevention of preterm labor, premature birth, dysmenorrhea and embryo implantation failure due to uterine contractions. The present invention is furthermore related to processes for their preparation.

Claim (Index 14):
The method of  claim 1 , wherein said dispersible tablet provides a bioavailability of (3Z,5S)-5-(hydroxymethyl)-1-[(2\u2032-methyl-1,1\u2032-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime of between 50% and 100% after administration to the patient.

Metadata:
- Claim Count in Document: 9.0
- Percentile: 91.0
- Lexical Diversity: 1.33929
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['14571615', '15476325', '14735215', '14479664', '15938729']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8176020010330667
- 35 USC 102 Novelty (BERT): 0.5746951114032192
- Combined Prediction Score: 0.793311312070082
- Mean Citation Score: 405.22407600000014
- Max Citation Score: 476.6411
- Similarity Product: 401.9973714558661

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test